BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

416 related articles for article (PubMed ID: 15598674)

  • 1. Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome.
    Ortega-González C; Luna S; Hernández L; Crespo G; Aguayo P; Arteaga-Troncoso G; Parra A
    J Clin Endocrinol Metab; 2005 Mar; 90(3):1360-5. PubMed ID: 15598674
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insulin sensitizing drugs increase the endogenous dopaminergic tone in obese insulin-resistant women with polycystic ovary syndrome.
    Ortega-González C; Cardoza L; Coutiño B; Hidalgo R; Arteaga-Troncoso G; Parra A
    J Endocrinol; 2005 Jan; 184(1):233-9. PubMed ID: 15642799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduction in hematocrit level after pioglitazone treatment is correlated with decreased plasma free testosterone level, not hemodilution, in women with polycystic ovary syndrome.
    Berria R; Gastaldelli A; Lucidi S; Belfort R; De Filippis E; Easton C; Brytzki R; Cusi K; Jovanovic L; DeFronzo R
    Clin Pharmacol Ther; 2006 Aug; 80(2):105-14. PubMed ID: 16890572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of metformin, orlistat and pioglitazone treatment on mean insulin resistance and its biological variability in polycystic ovary syndrome.
    Cho LW; Kilpatrick ES; Keevil BG; Coady AM; Atkin SL
    Clin Endocrinol (Oxf); 2009 Feb; 70(2):233-7. PubMed ID: 18547343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome.
    Pasquali R; Gambineri A; Biscotti D; Vicennati V; Gagliardi L; Colitta D; Fiorini S; Cognigni GE; Filicori M; Morselli-Labate AM
    J Clin Endocrinol Metab; 2000 Aug; 85(8):2767-74. PubMed ID: 10946879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity.
    Baillargeon JP; Jakubowicz DJ; Iuorno MJ; Jakubowicz S; Nestler JE
    Fertil Steril; 2004 Oct; 82(4):893-902. PubMed ID: 15482765
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pioglitazone and metformin in obese women with polycystic ovary syndrome not optimally responsive to metformin.
    Glueck CJ; Moreira A; Goldenberg N; Sieve L; Wang P
    Hum Reprod; 2003 Aug; 18(8):1618-25. PubMed ID: 12871871
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study.
    Morin-Papunen LC; Vauhkonen I; Koivunen RM; Ruokonen A; Martikainen HK; Tapanainen JS
    J Clin Endocrinol Metab; 2000 Sep; 85(9):3161-8. PubMed ID: 10999803
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pioglitazone for treating polycystic ovary syndrome in non-obese women of reproductive age with different clinical presentations.
    Koo YA; Shin SY; Yoon BK; Choi D
    Gynecol Endocrinol; 2007; 23(8):461-7. PubMed ID: 17852414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of rosiglitazone and metformin on oxidative stress and homocysteine levels in lean patients with polycystic ovary syndrome.
    Yilmaz M; Bukan N; Ayvaz G; Karakoç A; Törüner F; Cakir N; Arslan M
    Hum Reprod; 2005 Dec; 20(12):3333-40. PubMed ID: 16123091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inflammatory cytokines and chemokines, skeletal muscle and polycystic ovary syndrome: effects of pioglitazone and metformin treatment.
    Ciaraldi TP; Aroda V; Mudaliar SR; Henry RR
    Metabolism; 2013 Nov; 62(11):1587-96. PubMed ID: 23958241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of rosiglitazone and metformin on menstrual cyclicity and hirsutism in polycystic ovary syndrome.
    Yilmaz M; Karakoç A; Törüner FB; Cakir N; Tiras B; Ayvaz G; Arslan M
    Gynecol Endocrinol; 2005 Sep; 21(3):154-60. PubMed ID: 16335907
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome.
    Wu J; Zhu Y; Jiang Y; Cao Y
    Gynecol Endocrinol; 2008 Jul; 24(7):392-8. PubMed ID: 18608522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of rosiglitazone and metformin on insulin resistance and serum androgen levels in obese and lean patients with polycystic ovary syndrome.
    Yilmaz M; Biri A; Karakoç A; Törüner F; Bingöl B; Cakir N; Tiras B; Ayvaz G; Arslan M
    J Endocrinol Invest; 2005 Dec; 28(11):1003-8. PubMed ID: 16483179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-dose flutamide-metformin therapy reverses insulin resistance and reduces fat mass in nonobese adolescents with ovarian hyperandrogenism.
    Ibáñez L; Ong K; Ferrer A; Amin R; Dunger D; de Zegher F
    J Clin Endocrinol Metab; 2003 Jun; 88(6):2600-6. PubMed ID: 12788862
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of the insulin sensitizer pioglitazone on insulin resistance, hyperandrogenism, and ovulatory dysfunction in women with polycystic ovary syndrome.
    Brettenthaler N; De Geyter C; Huber PR; Keller U
    J Clin Endocrinol Metab; 2004 Aug; 89(8):3835-40. PubMed ID: 15292314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved efficacy of low-dose spironolactone and metformin combination than either drug alone in the management of women with polycystic ovary syndrome (PCOS): a six-month, open-label randomized study.
    Ganie MA; Khurana ML; Nisar S; Shah PA; Shah ZA; Kulshrestha B; Gupta N; Zargar MA; Wani TA; Mudasir S; Mir FA; Taing S
    J Clin Endocrinol Metab; 2013 Sep; 98(9):3599-607. PubMed ID: 23846820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study.
    Morin-Papunen L; Vauhkonen I; Koivunen R; Ruokonen A; Martikainen H; Tapanainen JS
    J Clin Endocrinol Metab; 2003 Jan; 88(1):148-56. PubMed ID: 12519844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of metformin compared with hypocaloric diet on serum C-reactive protein level and insulin resistance in obese and overweight women with polycystic ovary syndrome.
    Esfahanian F; Zamani MM; Heshmat R; Moini nia F
    J Obstet Gynaecol Res; 2013 Apr; 39(4):806-13. PubMed ID: 23279603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of the insulin sensitizer pioglitazone on menstrual irregularity, insulin resistance and hyperandrogenism in young women with polycystic ovary syndrome.
    Stabile G; Borrielli I; Artenisio AC; Bruno LM; Benvenga S; Giunta L; La Marca A; Volpe A; Pizzo A
    J Pediatr Adolesc Gynecol; 2014 Jun; 27(3):177-82. PubMed ID: 24814528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.